NFYB Inhibitors
NFYB inhibitors constitute a specialized class of compounds designed to target and inhibit the activity of NFYB (Nuclear Factor Y subunit B), a key component of the Nuclear Factor Y (NF-Y) transcription factor complex. NFY is involved in the regulation of a variety of genes, particularly those associated with cell cycle control, DNA repair, and the regulation of the immune response. The NF-Y complex is a trimer made up of NFYB, NFYA, and NFYC subunits, and it binds to specific DNA sequences known as CCAAT boxes, facilitating the transcription of target genes. By inhibiting NFYB, these compounds can disrupt this critical transcriptional regulation, thereby altering gene expression patterns within the cell.
The development of NFYB inhibitors typically relies on a detailed understanding of the structural biology of the NF-Y complex and its interaction with DNA. Researchers may employ high-throughput screening methods and rational drug design techniques to identify small molecules or peptides that can effectively block the function of NFYB. This can involve the design of compounds that compete with NFYB for binding to NF-YA or NFYC, thereby preventing the assembly of the NF-Y complex on DNA. Additionally, the specificity and potency of NFYB inhibitors are key considerations, as these compounds need to selectively target NFYB without affecting other transcription factors or cellular pathways. Overall, the exploration of NFYB inhibitors offers valuable insights into the complex mechanisms of gene regulation and the role of transcription factors in various cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin might downregulate NFYB expression by competing with NFYB for binding to the CCAAT box in gene promoters due to its effect on NF-κB, which can bind to similar regulatory elements. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol could attenuate NFYB expression by stimulating SIRT1, which may lead to deacetylation of histones near NFYB promoter regions, resulting in tighter chromatin and decreased transcription. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $153.00 $292.00 $489.00 $1325.00 $8465.00 $933.00 | 22 | |
DL-Sulforaphane may suppress NFYB expression through the activation of the Nrf2 pathway, potentially creating an antioxidant response that diverts cellular resources away from NFYB transcription. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate has the potential to repress NFYB expression by increasing histone acetylation levels, particularly around the NFYB promoter, leading to a closed chromatin configuration that is less transcriptionally active. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein might diminish NFYB expression by inhibiting tyrosine kinase activity, thereby disrupting intracellular pathways that normally stimulate transcription of the NFYB gene. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib could lead to a reduction in NFYB expression by blocking proteasome activity, which might cause the accumulation of repressive factors that hinder the transcription of NFYB. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine might lead to a decrease in NFYB transcription by inducing DNA hypomethylation at the NFYB gene promoter, which can result in a less favorable environment for the assembly of the transcriptional machinery. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid could lead to the repression of NFYB transcription by inhibiting histone deacetylase activity, which may change the acetylation status of histones around the NFYB gene and reduce transcriptional initiation. | ||||||
Oxaliplatin | 61825-94-3 | sc-202270 sc-202270A | 5 mg 25 mg | $112.00 $394.00 | 8 | |
Oxaliplatin could lead to a downregulation of NFYB expression by forming DNA adducts that hinder the binding of transcription factors or the assembly of transcriptional machinery at the NFYB gene. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide might curtail NFYB expression by altering the cellular cytokine milieu, particularly reducing TNF-α levels, which could lead to a less conducive environment for NFYB gene transcription. | ||||||